doxepin has been researched along with Chromosome-Defective Micronuclei in 1 studies
Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.
doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cobanoglu, H | 1 |
| Coskun, M | 2 |
| Çayir, A | 1 |
1 other study available for doxepin and Chromosome-Defective Micronuclei
| Article | Year |
|---|---|
In vitro genotoxic and cytotoxic effects of doxepin and escitalopram on human peripheral lymphocytes.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cell Survival; Citalopra | 2018 |